Infection and Immunity, March 2000, p. 1408-1417, Vol. 68, No. 3
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie1 and Pathologisches Institut,2 Ludwig-Maximilians-Universität, Munich, and Forschungsinstitut für Molekulare Pharmakologie, Abteilung für Molekulare Genetik, Berlin,3 Germany
Received 13 September 1999/Returned for modification 19 October 1999/Accepted 30 November 1999
| |
ABSTRACT |
|---|
|
|
|---|
Interferon consensus sequence binding protein (ICSBP)-deficient
mice display enhanced susceptibility to intracellular pathogens. At
least two distinct immunoregulatory defects are responsible for this
phenotype. First, diminished production of reactive oxygen intermediates in macrophages results in impaired intracellular killing
of microorganisms. Second, defective early interleukin-12 (IL-12)
production upon microbial challenge leads to a failure in gamma
interferon (IFN-
) induction and subsequently in T helper 1 immune
responses. Here, we investigated the role of ICSBP in resistance
against the extracellular bacterium Yersinia
enterocolitica. ICSBP
/
mice failed to produce
IL-12 and IFN-
, but also IL-4, after Yersinia challenge.
In addition, granuloma formation was highly disturbed in infected
ICSBP
/
mice, leading to multiple necrotic abscesses in
affected organs. Consequently, ICSBP
/
mice rapidly
succumbed to acute Yersinia infection. In vitro treatment
of spleen cells from ICSBP
/
mice with recombinant IL-12
(rIL-12) or rIL-18 in combination with a second stimulus resulted in
IFN-
induction. In experimental therapy of infected
ICSBP
/
mice, we observed that administration of rIL-12
induced IFN-
production which was associated with improved
resistance to Yersinia. In contrast, treatment with rIL-18
failed to enhance endogenous IFN-
production but nevertheless
reduced bacterial burden in ICSBP
/
mice. Although
cytokine therapy with rIL-12 or rIL-18 ameliorated the course of
Yersinia infection in ICSBP
/
mice, both
cytokines failed to completely restore impaired immunity. Taken
together, the results indicate that the transcription factor ICSBP is
essential for efficient host immune defense against
Yersinia. These results are important for understanding the
complex host immune responses in bacterial infections.
| |
INTRODUCTION |
|---|
|
|
|---|
Interferon (IFN) consensus
sequence binding protein (ICSBP) (19) belongs to the
IFN regulatory factor (IRF) family of mammalian transcription factors
(see for a review reference 47). Proteins of the IRF
family bind to the IFN-stimulated response element (ISRE) and control
transcription of genes with ISREs within their promoter regions
(57). The IRF family plays an important role in the
regulation of both type I (IFN-
/
) and type II (IFN-
) IFN-inducible genes. ICSBP is exclusively expressed in
hematopoietically derived cells and predominantly induced by IFN-
(25, 55). Analyses of recently generated ICSBP knockout
(ICSBP
/
) mice have permitted insights into the in vivo
role of ICSBP (34). These mice exhibit a chronic myelogenous
leukemia (CML)-like syndrome and display enhanced susceptibility to a
variety of intracellular pathogens including Listeria
monocytogenes, Leishmania major, and Toxoplasma
gondii (22, 28, 34, 64). ICSBP
/
mice
fail to develop T helper 1 (Th1)-driven immune responses due to a
primary defect in interleukin-12 (IL-12) p40 induction and, as a
consequence, IFN-
-dependent host resistance (28, 34, 64).
Furthermore, ICSBP
/
mice show reduced and delayed
oxidative burst, whereas nitric oxide (NO) production is normal
(22). Th2 immune responses, however, are not affected in
these mice. In addition, ICSBP modulates survival of myeloid cells by
regulating expression of apoptosis-related genes (26).
Yersinia enterocolitica is enteropathogenic for humans and rodents. The bacteria cross the intestinal epithelial barrier by translocating through M cells, spread into the lamina propria, and colonize preferentially the underlying Peyer's patches (2, 4, 14, 29, 30). Virulence plasmid (pYV)-harboring strains are able to migrate from the Peyer's patches to the mesenteric lymph nodes and deeper organs such as the spleen, liver, and lungs, where they multiply extracellularly and lead to the formation of multiple necrotic abscesses (2, 4, 30, 69). In contrast, nonvirulent strains lacking the pYV (pCD1 in Y. pestis) plasmid are contained within granulomas, resulting in a lower rate of infection before rapid clearance of the bacteria (45, 71, 74).
Successful control and elimination of Y. enterocolitica
depends on both innate and adaptive immunity. Neutrophils and
macrophages are involved in partial restriction of bacterial
replication in the early phase of primary infection in mice
(4, 15, 31, 62). Furthermore, despite Y. enterocolitica being an extracellular pathogen, it is well
established that T-cell-mediated and IFN-
-dependent immune
mechanisms are essential for resistance (1, 5).
Consequently, adoptive transfer of Yersinia-specific
CD4+ Th1 cell clones into athymic T-cell-deficient nude
mice confers resistance against this pathogen (6). Previous
studies have shown that C57BL/6 mice, which produce high levels of
IFN-
, are resistant to Y. enterocolitica, whereas BALB/c
mice, which secrete only small quantities of IFN-
, are susceptible
to Yersinia infection (1). Furthermore,
neutralization or genetic deletion of the cytokine tumor necrosis
factor alpha (TNF-
), IFN-
, IL-12, or IL-18 abrogates resistance
to Yersinia infection (3, 7, 10). Based on these
results, it is conceivable that antigen-presenting cells such as
dendritic cells and macrophages become activated during contact with
microbes and start producing IL-12 and IL-18. These cytokines strongly
induce the expression of IFN-
in natural killer (NK) cells and
CD4+ Th1 cells. Most likely, IFN-
produced by these
cells synergizes with macrophage-produced TNF-
to activate
microbicidal mechanisms such as reactive oxygen intermediates and
reactive nitrogen intermediates in macrophages.
Although ICSBP has been shown to be essential for immunity to
intracellular pathogens, nothing is known about its requirement for
immunity to extracellular pathogens, in particular Y. enterocolitica. The aim of this study was to investigate (i)
whether ICSBP
/
mice exhibit an altered susceptibility
to Yersinia, (ii) which defense mechanisms against
Yersinia depend on the coordinate expression of the
transcription factor ICSBP, and (iii) whether administration of
recombinant cytokines restores impaired immunity in
ICSBP
/
mice. The experiments described herein argue for
an essential role of ICSBP in resistance against Y. enterocolitica.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Mice.
Young ICSBP
/
mice, 6 to 10 weeks old,
on a C57BL/6 × 129/Sv or C57BL/6 background were used for all
experiments, as they do not display the severe CML-like disease which
develops in aged animals (34). Control C57BL/6 × 129/Sv or C57BL/6 mice were purchased from Charles River Wiga
(Sulzfeld, Germany). All animals were housed in specific-pathogen-free
conditions in negative-pressure cabinets.
Bacteria, experimental infection, and in vivo administration of
cytokines.
Plasmid (pYV)-harboring Y. enterocolitica
WA-314 (serotype O:8) was used for intravenous (i.v.) infection as
previously described (33). In brief, Y. enterocolitica was passaged in mice, cultivated at 26°C in Luria
broth, harvested during the log phase, aliquoted, and frozen at
80°C. Surface expression of YadA was tested by agglutination using
anti-YadA polyclonal antiserum. For experimental infection, freshly
thawed bacteria diluted in sterile phosphate-buffered saline (PBS; pH
7.4) to obtain the indicated dose were injected i.v. in a total volume
of 100 µl. The actual number of bacteria administered was determined
by plating serial dilutions of the inoculum on Mueller-Hinton agar.
Mice were weighed before infection and every day after infection. On
the indicated days after infection, the spleen and liver were taken out
and homogenized. Bacterial titers were determined by plating out serial
10-fold dilutions of organ suspensions on Mueller-Hinton agar. The
limit of detectable CFU was 25 (log 1025 = 1.4). Mice
were treated by intraperitoneal (i.p.) administration of PBS, murine
recombinant IFN-
(rIFN-
) (a gift from Bender, Vienna, Austria),
murine rIL-12 (kindly provided by M. Gately), and murine rIL-18 (kindly
provided by H. Okamura) over 5 days starting 1 day prior to infection.
Histology and immunohistology.
Histological and
immunohistological examinations were performed as previously described
(4). For histological examinations, the liver and spleen
were excised, fixed in 4% buffered formalin, embedded in paraffin,
cut, and stained. For immunohistological analysis, the tissues were
embedded in Tissue-Tek O.C.T. compound (Nunc, Roskilde, Denmark),
snap-frozen in liquid nitrogen, and stored at
80°C. Frozen sections
were prepared and double immunostainings were performed. Nonspecific
binding sites were blocked by incubation of the sections with PBS
containing 25% sheep serum. Then sections were incubated with rabbit
anti-Y. enterocolitica O:8 antibodies (diluted 1:100)
followed by alkaline phosphatase-conjugated goat anti-rabbit antibody
diluted 1:100. Substrate solution (9.8 ml of Tris buffer [pH 8.2]
containing 10 ml of levamisole, 20 mg of naphthol-AS-MX-phosphate, and
10 mg of fast red salt) was incubated for 20 min. Then an indirect
three-stage immunoperoxidase method (peroxidase-antiperoxidase [PAP])
including 3,3-diaminobenzidine tetrahydrochloride acid (Sigma,
Deisenhofen, Germany) as indicator was used for detection of
immunolabeling with anti-Mac-1 (5C6) antibodies (hybridoma cell culture
supernatant diluted 1:10). Peroxidase-conjugated mouse
F(ab')2 fragment anti-rat immunoglobulin G (diluted 1:100;
Dianova, Hamburg, Germany) was used as secondary antibody, and rat PAP
complex (diluted 1:100; Dianova) was used as tertiary antibody. After
incubation with substrate solution, the sections were counterstained
with Mayer's hematoxylin, mounted, and assessed microscopically by two
independent investigators. Isotype-matched irrelevant antibodies were
used as controls and revealed no staining signal.
Cell preparation, culture conditions, and in vitro stimulation of cells. Single-cell suspensions were prepared from spleen for tissue culture. In brief, erythrocytes were lysed with ammonium chloride lysing buffer (0.15 M NH4Cl [pH 7.2]), and the remaining cells were washed three times with Hanks balanced salt solution and resuspended in Click/RPMI 1640 cell culture medium supplemented with 10% heat-inactivated fetal calf serum, streptomycin (10 µg/ml), penicillin (100 U/ml), 2 mM L-glutamine, 10 mM HEPES, and 50 µM 2-mercaptoethanol (Biochrom, Berlin, Germany). For in vitro studies, 106 cells per ml were cultured for 48 h at 37°C in a humidified 5% CO2 atmosphere. For determination of cytokine production, cells were incubated in the presence of medium alone, concanavalin A, heat-killed Yersinia (HKY), rIL-12, and rIL-18 as indicated.
Determination of cytokine production in cell culture supernatants
and sera.
IFN-
levels were determined by using a capture
enzyme-linked immunoadsorbent assay (ELISA). Briefly, ELISA microtiter
plates (Greiner, Frickenhausen, Germany) were coated with
anti-IFN-
monoclonal antibody (MAb) (AN-18.17.24). After
blocking of nonspecific binding sites, sera or supernatants were added
to the wells and incubated overnight. After several wash steps,
biotin-labeled anti-IFN-
MAb (R4-6A2) was added. Finally, an
avidin-biotin-alkaline phosphatase complex (Strept ABC-AP kit; DAKO,
Glostrup, Denmark) was added. For signal development, the wells were
incubated with p-nitrophenyl phosphate disodium (Sigma), and
the optical density was determined at wavelengths of 405 and 490 nm
with an ELISA reader. The level of IFN-
from spleen cell culture was
determined from the straight-line portion of the standard curve by
using recombinant murine IFN-
.
and IL-12 (p40 and p70) levels were determined by a capture
ELISA using (i) anti-TNF-
MAb (G281-2626) and biotin-labeled anti-TNF-
MAb (MP6XT3) and (ii) anti-IL-12 MAb (C17.8) and
biotin-labeled anti-IL-12 MAb (C15.6) (Pharmingen, Hamburg, Germany),
respectively, as described above for IFN-
ELISA.
IL-4 was measured using a bioassay employing IL-4-dependent CTS4 cells.
Single-cell suspensions of splenocytes derived from infected
ICSBP+/+ and ICSBP
/
mice were cultured
under conditions described above; after 48 h, supernatants were
collected and assayed for IL-4 activity. Then 5 × 103
CTS4 cells were added to serial dilutions of supernatants. Cells were
incubated for 24 h in an humidified 37°C, 5% CO2
incubator and pulsed with [3H]thymidine for an additional
24 h. [3H]thymidine incorporation was measured by
liquid scintillation counting. The limit of detection was 5 U of IL-4
per ml.
Purification of RNA, cDNA synthesis, and RT-PCR analysis of
cytokine mRNA.
Approximately 100 mg of tissue was homogenized in 1 ml of TRIzol (Gibco-Life Technologies, Karlsruhe, Germany), and total RNA was isolated by a single-step method as described elsewhere (13). Reverse transcription (RT) was performed by mixing 20 µg of RNA in 10 µl of diethyl pyrocarbonate-treated
double-distilled H2O with 0.5 µg of oligo(dT) (Gibco).
This solution was incubated for 10 min at 65°C. Then 10 µl of a
solution containing 4 µl of 5× reverse transcriptase buffer (100 mM
Tris-HCl [pH 8.3], 150 mM KCl, 6 mM MgCl2) (Gibco), 40 U
of RNasin (Promega, Mannheim, Germany), 20 mM dithiothreitol (Gibco),
and 2 mM deoxynucleoside triphosphates was added, and tubes were
incubated for 60 min at 37°C. Finally, tubes were heated to 90°C
for 5 min, and 180 µl of distilled H2O was added to the
reaction mixture. Samples were stored at
20°C until further use.
Five microliters of cDNA prepared as described above was added to 50 µl of a solution consisting of 1 U of AmpliTaq or AmpliTaq Gold DNA
polymerase (Perkin-Elmer, Norwalk, Conn.), 200 µM deoxynucleoside
triphosphates, 200 nM sense and antisense primers, and 5 µl of 10×
PCR buffer (50 mM KCl, 10 mM Tris-HCl [pH 8.3], 1.5 mM
MgCl2; Perkin-Elmer). As indicated in Table
1, 21 to 40 PCR cycles consisting of
denaturation (30 s at 94°C), annealing (45 s at 60°C), and
amplification (60 s at 72°C) were carried out on a DNA thermal cycler
(GeneAmp PCR System 9600; Perkin-Elmer). PCR amplification was started
by an initial denaturation step (5 min at 94°C) and completed by a
final amplification step (7 min at 72°C); 20 µl of the PCR product
was mixed with 5 µl of 5× gel loading buffer and subjected to
electrophoresis on a 2% agarose gel. PCR products were visualized by
staining with ethidium bromide. The sequences of sense and antisense
primers used in this study are shown in Table 1.
|
Statistics. Statistical analysis of data was carried out using the Student t test. P < 0.05 was considered statistically significant. All experiments have been repeated at least once and revealed comparable results.
| |
RESULTS |
|---|
|
|
|---|
ICSBP
/
mice succumb to acute infection with
Y. enterocolitica.
To assess the role of ICSBP in resistance
against extracellularly located Yersinia, wild-type (wt) and
gene-deficient mice were infected i.v. with 3 × 103
CFU of a virulent strain. This dose corresponds to 0.1 median lethal
dose in C57BL/6 mice. Since differences in the genetic background of
inbred mice affect immunity against Yersinia,
ICSBP
/
mice on a randomly mixed C57BL/6 × 129/Ola background and ICSBP
/
mice on a C57BL/6
background, which is normally resistant to Yersinia, were
tested in comparison to the corresponding wt mice. All wt mice survived
and appeared healthy, whereas 7 out of 15 ICSBP
/
mice
(5 out of 10 mice on a C57BL/6 × 129/Ola background and 2 out of
5 mice on a C57BL/6 background) succumbed to infection. Surviving
ICSBP
/
animals were severely compromised and developed
a wasting-like syndrome with weight loss within 3 to 4 days after
infection (data not shown). These mice showed multiple abscesses in the
spleen and liver, whereas only marginal changes were found in wt mice. ICSBP
/
mice exhibited significantly higher bacterial
numbers in spleens compared to wt animals (Fig.
1). These data indicate that immune mechanisms contributing to resistance against Yersinia are
regulated by the transcription factor ICSBP. For all further
experiments, ICSBP+/+ and ICSBP
/
mice on a
C57BL/6 background were used.
|
Impaired IL-12 and IFN-
production of ICSBP
/
mice in response to Yersinia.
To determine whether the
enhanced susceptibility to Y. enterocolitica in
ICSBP
/
mice correlates with an altered pattern in
cytokine production, gene expression was analyzed in
Yersinia-infected ICSBP+/+ and
ICSBP
/
mice by RT-PCR. IL-12 p40 and IFN-
mRNA
expression was markedly reduced, whereas IL-12 p35 mRNA was upregulated
in ICSBP
/
mice (Fig. 2).
In contrast to infections with intracellular L. major
(28) or T. gondii (64), IL-4 mRNA was
not detectable in ICSBP
/
mice after infection with
Y. enterocolitica. Furthermore, mRNA expression levels of
IL-10, IL-18, and TNF-
(Fig. 2), as well as IL-15 and IL-12 receptor
1 and
2 (data not shown), did not differ between
ICSBP+/+ and ICSBP
/
mice.
|
/
mice (Fig. 3A).
Although we did not detect high levels of IFN-
in sera of
ICSBP+/+ mice on day 4 after infection with
Yersinia (Fig. 3A), spleen cells of these mice showed
substantial IFN-
production after in vitro restimulation with HKY
(Fig. 3B). In contrast, spleen cells of infected ICSBP
/
mice failed to produce IFN-
after in vitro restimulation (Fig. 3B).
Both ICSBP
/
and ICSBP+/+ splenocytes did
not produce IL-4 in vitro (Fig. 3B). Previous work (1, 8)
showed that BALB/c mice did not produce IL-4 upon Yersinia
infection, indicating that susceptibility to this pathogen is caused by
a defect in IFN-
-mediated immune responses rather than by a switch
to Th2 immune responses. These data suggest that ICSBP is required for
sufficient IL-12 and IFN-
production in response to
Yersinia.
|
ICSBP
/
mice reveal a failure in granuloma formation
after challenge with Yersinia.
To assess whether ICSBP
deficiency affects granuloma formation, histological and
immunohistological examinations of the liver and spleen after
Yersinia infection were performed. ICSBP+/+ mice
exhibited well-demarcated, small granuloma-like lesions, whereas
ICSBP
/
mice showed an extensive and protracted tissue
destruction with multiple necrotic abscesses (Fig.
4). While Yersinia was hardly detectable by immunohistological analysis in wt mice, large numbers of
bacteria were observed in ICSBP
/
animals.
Yersinia was located either extracellularly in areas of
necrosis or phagocytosed in macrophages or Kupffer cells but not in
hepatocytes.
|
/
mice lacked a distinct demarcation by
Mac-1+ cells. Moreover, many of these cells were scattered
in liver and spleen tissues of infected ICSBP
/
mice.
These results show that ICSBP is critical for granuloma formation, an
important step for the control of infections caused by
Yersinia.
Spleen cells from ICSBP
/
mice are able to produce
IFN-
after treatment with rIL-12 or rIL-18 in combination with a
second stimulus.
Previous studies have shown that splenic
lymphocytes from ICSBP
/
mice are able to produce
IFN-
upon appropriate stimulation (28, 34, 64, 77). To
investigate whether cytokine treatment using strong IFN-
inducers
such as IL-12 or IL-18 can restore impaired IFN-
-dependent
resistance against Yersinia in ICSBP
/
mice,
IFN-
production of naive spleen cells was determined following in
vitro stimulation. Both rIL-12 and rIL-18 given alone failed to induce
IFN-
(Fig. 5A). These cytokines,
however, combined with HKY resulted in low levels of IFN-
production in spleen cells of ICSBP
/
mice (Fig.
5A). Moreover, combined stimulation with rIL-12 and rIL-18 caused a
strong dose-dependent increase in IFN-
production in spleen
cells from both ICSBP+/+ and ICSBP
/
mice (Fig. 5B and C). Although IFN-
production was still
considerably lower in ICSBP
/
mice than in wt animals,
these results indicated that the defect of ICSBP
/
mice
to produce IFN-
was only in part intrinsic and might be curable by
exogenous delivery of IFN-
-inducing cytokines.
|
Administration of rIL-12, but not rIL-18, augments IFN-
synthesis in Yersinia-infected ICSBP
/
mice.
We have demonstrated that either rIL-12 or rIL-18 in
combination with a second stimulus induces IFN-
in
splenocytes of ICSBP
/
mice. Therefore, IFN-
production in Yersinia-infected ICSBP
/
mice was examined after treatment with rIL-12 or rIL-18. In these experiments, Y. enterocolitica served as a second stimulus
for IFN-
induction. As shown in Fig.
6A, rIL-12 amplified IFN-
mRNA expression in Yersinia-infected ICSBP
/
mice,
whereas rIL-18 stimulated only little, if any, IFN-
production. In
addition, significantly higher protein levels for both IL-12 and
IFN-
were detected in sera of ICSBP
/
mice after
treatment with rIL-12 compared to those after administration of rIL-18 (Fig. 6B). However, we cannot exclude that a dose
higher than 1 µg per day or a different application scheme for
rIL-18 may induce IFN-
in ICSBP
/
mice. The
protein levels for IL-12 in treated mice were mainly due to injected
rIL-12.
|
induction restored antibacterial resistance, we
investigated the role of rIL-12 or rIL-18 in the course of Yersinia infection in ICSBP
/
mice.
Administration of rIL-12 improved survival of
Yersinia-infected ICSBP
/
mice but reduced
bacterial load in spleen and livers of ICSBP
/
mice only
about 10-fold (Fig. 7). We observed only
minimal differences in the effect of rIL-12 between
ICSBP
/
mice infected with a medium dose (3 × 103 CFU) (Fig. 7A) or a low dose (3 × 102
CFU) (Fig. 7B and C) of Yersinia. Administration of 1 µg
of rIL-18 per day, but not lower doses, decreased Yersinia
counts in ICSBP
/
mice (Fig. 7A and C).
Semiquantitative analysis of immunohistological examinations revealed
that treatment by both rIL-12 and rIL-18 leads to a reduction of
Yersinia and necrotic lesions and to a small increase of
Mac1+ cells in infected organs (Table
2).
|
|
has been shown to decrease bacterial
load in susceptible BALB/c mice (1). However, experimental therapy with rIFN-
(105 IU/day) diminished
bacterial counts in affected organs of ICSBP
/
mice only about 10-fold (data not shown). In addition,
experimental therapy by a combination of rIL-12 (10 ng/day) and rIL-18
(100 ng/day) failed to reduce bacterial load more efficiently than the
corresponding dose of rIL-12 given alone (data not shown). Again,
we cannot exclude that a more drastic reduction of Yersinia titers could be achieved by a combined IL-12 and IL-18 therapy using higher doses of both cytokines. However, the doses of recombinant cytokines used in this study are comparable to those employed by others
(24, 51, 56, 64). Thus, experimental cytokine therapy
ameliorated the course of Yersinia infection in
ICSBP
/
mice but failed to completely restore immunity.
| |
DISCUSSION |
|---|
|
|
|---|
The aim of this study was to analyze the role of the mammalian
transcription factor ICSBP in host resistance to the extracellular bacterium Y. enterocolitica. ICSBP
/
mice
rapidly succumbed to acute microbial infection and failed to produce
sufficient amounts of IL-12 and IFN-
after bacterial challenge. In
contrast to infection with intracellular pathogens, we could not
observe a shift toward Th2 immune responses in
Yersinia-infected ICSBP
/
mice (28,
64). Moreover, granuloma formation, which is a hallmark of
protective immune responses against Yersinia, was highly
disturbed in these mice. In contrast to our in vitro data, rIL-12 but
not rIL-18 restored Yersinia-triggered IFN-
production in
infected ICSBP
/
mice. Although treatment of
ICSBP
/
mice with rIL-12 or rIL-18 improved survival and
reduced bacterial load, both cytokines failed to completely restore
impaired immunity.
Resistance to Yersinia depends on the coordinate expression
of the cytokines IFN-
, IL-12, IL-18, and TNF-
(1,
7-10). Neutralization of any of these cytokines abrogates
clearance of bacteria in infected mice (3, 7, 10). In
addition, studies of Yersinia infection in mice deficient
for IL-12 p40, IL-18, IFN-
receptor, or TNF receptor p55 have
confirmed the crucial role of these cytokines (9). Although
all T-lymphocyte subpopulations are required for optimum protection
against Yersinia, IFN-
production by CD4+ T
cells is indispensable to promote bacterial clearance (1).
In contrast to previous studies characterizing the phenotype of
ICSBP
/
mice using the intracellular pathogens L. major and T. gondii (28, 64), we could not
detect any IL-4 production or Th2 dominance in these mice during
Yersinia infection. In fact, IL-4 mRNA expression levels were even lower in ICSBP
/
mice than in
ICSBP+/+ mice. These findings are consistent with a
previous report showing that Yersinia-susceptible BALB/c
mice express less IL-4 mRNA than Yersinia-resistant C57BL/6
mice (1, 8). Although it is well established that IFN-
is
crucial for resistance to Yersinia, the reason for this
observation is unclear. Thus, the role of Th2 cytokines such as IL-4 or
IL-10 in Yersinia infection remains to be investigated.
The obvious defect of ICSBP
/
mice in control of
extracellular Yersinia is at least partially due to the
inability of their antigen-presenting cells to produce IL-12 and, as a
consequence, to confer sufficient T-cell-mediated activation of
macrophages by IFN-
. However, in vitro stimulation of splenic T
cells from ICSBP
/
mice showed that these cells are able
to produce IFN-
under appropriate stimulation. Moreover, the
apparent defect of ICSBP
/
mice to secrete IFN-
after
Yersinia infection could be restored by exogenous delivery
of rIL-12. Although administration of rIL-12 ameliorated the course of
bacterial infection, it did not result in complete restoration of
resistance against Yersinia. These data suggest that
additional, probably IL-12- and IFN-
-independent defense mechanisms
are also regulated by the transcription factor ICSBP.
Like IL-12, IL-18 is a potent inducer of IFN-
and important for NK
cell activity and Th1 immune responses (48, 58, 72). In
contrast to a recent publication, we did not observe a regulatory effect of ICSBP on the expression of IL-18 in infected mice
(39). Interestingly, rIL-18 failed to enhance IFN-
synthesis in infected ICSBP
/
mice but nevertheless
reduced bacterial replication similarly to IL-12 therapy. Although the
doses of rIL-18 used in this study are comparable to those employed by
others (24, 51), we cannot definitively exclude that a
higher dose of this cytokine amplifies IFN-
production and protects
more efficiently against Yersinia, as shown for infections
caused by Cryptococcus neoformans (38). However,
our data indicate that endogenous IL-12 is required for IL-18-mediated
induction of measurable quantities of IFN-
in infected mice. Whether
IL-18 is involved in IFN-
-independent immune responses remains to be investigated.
The mechanisms by which ICSBP regulates gene transcription appear to be
complex. Previous in vitro studies have shown that ICSBP is a negative
regulator of several IFN-responsive genes such as the major
histocompatibility complex class I genes (46, 75, 76). In
contrast, recent analyses implicate ICSBP as an activator of gene
transcription for IL-12 p40 and cytochrome b558 heavy-chain gene (CYBB), the gene encoding
gp91phox, a subunit of the phagocyte respiratory
burst oxidase catalytic unit (21, 28, 64). This dichotomy in
ICSBP function is not completely unexpected since other transcription
factors have been shown to act positively or negatively depending on
the context. ICSBP forms complexes with other IRF family members such
as IRF-1 and IRF-2 that strongly bind to ISREs (12, 67, 68).
Interestingly, the ability of IRF-1
/
mice to produce
IL-12 is severely compromised (40, 73). Although several major differences exist between IRF-1
/
and
ICSBP
/
mice, these data suggest that a heterodimer
composed of IRF-1 and ICSBP regulates IL-12 p40 expression.
Furthermore, the Ets family transcription factor PU.1, which is
exclusively expressed in myeloid and B cells, cooperates with ICSBP in
gene expression (20, 21). Thus, regulation of ICSBP-mediated
gene expression and suppression depends heavily on the proper balance
of transcription factors bound to this molecule.
The data presented here argue for a crucial role of ICSBP in resistance
to Yersinia. ICSBP is involved in signal transduction events
downstream from the IFN-
receptor enhancing IL-12 p40 and
CYBB gene expression. Since macrophages of ICSBP
/
mice are capable of responding to IFN-
and producing NO, ICSBP affects only a subset of IFN-
-inducible genes (21, 22, 28, 34,
64). IL-12 p40 mRNA expression has been detected in mice 1 day
after i.v. infection with Yersinia (7). However,
it remains to be investigated whether IL-12 p40 synthesis in infected
mice is directly induced by microbial products of invading
Yersinia or requires endogenous IFN-
. The former would
argue for a second receptor involved in IL-12 p40 induction after
Yersinia infection. In this model, ICSBP regulates both the
IFN-
-dependent and IFN-
-independent, but
Yersinia-dependent, pathway of IL-12 p40 synthesis. We have shown that IL-12 is essential for resistance against
Yersinia by triggering IFN-
production in NK cells and
CD4+ T cells (7). Therefore, one mechanism of
ICSBP to confer resistance against Yersinia is based on its
requirement for IL-12 p40 induction and, as a consequence, IFN-
production.
Interestingly, virulence plasmid-containing strains of
Yersinia are capable of suppressing the cytokine production
of their host during infection. Thus, it is tempting to speculate
whether bacterial factors function by blocking ICSBP or disrupting
signal transduction pathways which regulate the induction and
activation of transcription factors of the IRF and Ets family. The
70-kb virulence plasmid (pYV/pCD1) of Yersinia encodes a
contact-dependent type III secretion system (see for reviews reference
16 to 18 and
35). pYV+/pCD1+-harboring
strains are able to abrogate the generic inflammatory response in mice
by downregulating IFN-
and TNF-
(44). Priming by
injection of proinflammatory cytokines before infection or passive
immunization with antiserum against LcrV (or V antigen) later
facilitates the inflammatory response and granuloma formation, thereby
preventing lethality (44). In addition, recombinant LcrV
inhibits synthesis of IFN-
and TNF-
in mice challenged with
avirulent, i.e., plasmid-cured, Yersinia, suggesting that this virulence factor prevents inflammation (45).
Furthermore, recent findings have shown that suppression of TNF-
by
an LcrV-containing fusion protein requires the presence of activated T
cells and does not depend on cell-to-cell contact, indicating that this effect is mediated by an as yet unknown soluble factor (66). However, cytokine suppression by virulence plasmid-containing Yersinia has also been attributed to the action of type III
secreted virulence factors (referred to as Yersinia outer
proteins, or Yops), especially YopP (YopJ in Y. pestis and
Y. pseudotuberculosis). This protein perturbs a multiplicity
of signaling pathways including inhibition of the extracellular
signal-regulated kinase, c-Jun NH2-terminal kinase, and p38
mitogen-activated protein kinase pathways and inhibition of the NF-
B
pathway (11, 50, 52, 53, 59, 60, 65). The interruption of
these signaling pathways inhibits expression of TNF-
and IL-8 and
induces apoptosis in the infected target cell (11, 42, 43, 52, 59,
61, 65).
Two models of LcrV function are currently discussed (23, 54, 63). In the first model, Yop effector proteins are translocated by an LcrV-independent mechanism. LcrV is exported from the bacterium to directly prevent the inflammatory response of the host. In the second model, LcrV is involved in virulence protein translocation into the host cell. This would argue for an indirect effect of LcrV on cytokine suppression since the cytotoxins themselves inhibit the inflammatory response.
In view of the above, targeting of ICSBP or signal transduction
pathways upstream from ICSBP by a Yersinia virulence protein would impair IL-12 p40 synthesis. Whether IFN-
inhibition by Yersinia is secondary to IL-12 suppression remains to be
investigated. In addition, intracellular trafficking of a
Yersinia factor through the nuclear pore into the nucleus is
a prerequisite for the direct interaction with the transcription factor
ICSBP. The only Yersinia virulence protein known to do so is
YopM, a strongly acidic protein containing multiple leucine-rich repeat
motifs (70). However, its intracellular target and mode of
action has not been identified.
Beside the defects in cytokine production, impaired macrophage effector
functions may also contribute to the increased susceptibility of
ICSBP
/
mice to infectious agents (37, 41). A
recent study of mice deficient for IRF-1, IRF-2, and ICSBP in
resistance to the intracellular bacterium L. monocytogenes
demonstrated that the oxidative burst was delayed and reduced in
ICSBP
/
mice, whereas NO production was normal
(22). Furthermore, it has been shown that PU.1, IRF-1, and
ICSBP together increase gp91phox protein
expression, a subunit of a membrane-bound flavocytochrome involved in
the regulation of the oxidative burst (21). The absence of
gp91phox protein leads to chronic granulomatous
disease, a disorder of host defense (49). In addition, the
fact that ICSBP
/
mice display a CML-like disorder
further supports the crucial role of ICSBP for the development and
function of cells of the myeloid lineage such as macrophages and
neutrophils (34). T lymphocytes, however, seem to be only
slightly affected in these mice. It has been shown that adoptively
transferred splenic T cells of ICSBP
/
mice were able to
promote elimination of Listeria in RAG2
/
mice which lack functional B and T cells (22).
As previously suggested, other mechanisms involved in resistance
against bacterial pathogens might also be regulated by the transcription factor ICSBP (22). For example, iron
metabolism is a primitive but crucial defense mechanism against
microorganisms, and iron overload syndromes are associated with severe
systemic or septicemic infection with Y. enterocolitica
(27, 36). Moreover, Yersinia spp., which have an
absolute requirement for iron, developed sophisticated mechanisms like
the siderophore system to acquire iron from their host (32).
Interestingly, increased iron load was measured in sera of uninfected
ICSBP mice compared to wt animals (J. Hein, R. Gruber, and I. B. Autenrieth, unpublished data). Whether and how ICSBP is involved in
iron withholding and whether this parameter affects Yersinia
infection in ICSBP
/
mice remain to be investigated.
In conclusion, we showed that the transcription factor ICSBP confers
resistance against the extracellular bacterium Y. enterocolitica. Further studies are required to elucidate
additional molecular defects of ICSBP
/
mice resulting
in their increased susceptibility to Yersinia.
| |
ACKNOWLEDGMENTS |
|---|
We thank Maurice K. Gately and Haruki Okamura for providing reagents and Ralf Schulte and Heinrich Körner for critical reading.
This work was supported by a grant from the Deutsche Forschungsgemeinschaft (SFB 217).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Max von Pettenkofer-Institut, Ludwig-Maximilians-Universität München, Pettenkoferstrasse 9a, D-80336 Munich, Germany. Phone: 49-89-5160-5280. Fax: 49-89-5160-5223. E-mail: autenrieth{at}m3401.mpk.med.uni-muenchen.de.
Present address: Institut für Klinische Mikrobiologie,
Immunologie und Hygiene, Friedrich-Alexander Universität
Erlangen-Nürnberg, D-91054 Erlangen, Germany.
Editor: J. D. Clements
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Autenrieth, I. B.,
M. Beer,
E. Bohn,
S. H. Kaufmann, and J. Heesemann.
1994.
Immune responses to Yersinia enterocolitica in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon.
Infect. Immun.
62:2590-2599 |
| 2. | Autenrieth, I. B., and R. Firsching. 1996. Penetration of M cells and destruction of Peyer's patches by Yersinia enterocolitica: an ultrastructural and histological study. J. Med. Microbiol. 44:285-294[Abstract]. |
| 3. | Autenrieth, I. B., and J. Heesemann. 1992. In vivo neutralization of tumor necrosis factor-alpha and interferon-gamma abrogates resistance to Yersinia enterocolitica infection in mice. Med. Microbiol. Immunol. 181:333-338[Medline]. |
| 4. | Autenrieth, I. B., V. Kempf, T. Sprinz, S. Preger, and A. Schnell. 1996. Defense mechanisms in Peyer's patches and mesenteric lymph nodes against Yersinia enterocolitica involve integrins and cytokines. Infect. Immun. 64:1357-1368[Abstract]. |
| 5. |
Autenrieth, I. B.,
A. Tingle,
A. Reske-Kunz, and J. Heesemann.
1992.
T lymphocytes mediate protection against Yersinia enterocolitica in mice: characterization of murine T-cell clones specific for Y. enterocolitica.
Infect. Immun.
60:1140-1149 |
| 6. |
Autenrieth, I. B.,
U. Vogel,
S. Preger,
B. Heymer, and J. Heesemann.
1993.
Experimental Yersinia enterocolitica infection in euthymic and T-cell-deficient athymic nude C57BL/6 mice: comparison of time course, histomorphology, and immune response.
Infect. Immun.
61:2585-2595 |
| 7. | Bohn, E., and I. B. Autenrieth. 1996. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells. J. Immunol. 156:1458-1468[Abstract]. |
| 8. |
Bohn, E.,
J. Heesemann,
S. Ehlers, and I. B. Autenrieth.
1994.
Early gamma interferon mRNA expression is associated with resistance of mice against Yersinia enterocolitica.
Infect. Immun.
62:3027-3032 |
| 9. |
Bohn, E.,
E. Schmitt,
C. Bielfeldt,
A. Noll,
R. Schulte, and I. B. Autenrieth.
1998.
Ambiguous role of interleukin-12 in Yersinia enterocolitica infection in susceptible and resistant mouse strains.
Infect. Immun.
66:2213-2220 |
| 10. |
Bohn, E.,
A. Sing,
R. Zumbihl,
C. Bielfeldt,
H. Okamura,
M. Kurimoto,
J. Heesemann, and I. B. Autenrieth.
1998.
IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice.
J. Immunol.
160:299-307 |
| 11. |
Boland, A., and G. R. Cornelis.
1998.
Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection.
Infect. Immun.
66:1878-1884 |
| 12. |
Bovolenta, C.,
P. H. Driggers,
M. S. Marks,
J. A. Medin,
A. D. Politis,
S. N. Vogel,
D. E. Levy,
K. Sakaguchi,
E. Appella, and J. E. Coligan.
1994.
Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family.
Proc. Natl. Acad. Sci. USA
91:5046-5050 |
| 13. | Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159[Medline]. |
| 14. |
Clark, M. A.,
B. H. Hirst, and M. A. Jepson.
1998.
M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells.
Infect. Immun.
66:1237-1243 |
| 15. | Conlan, J. W. 1997. Critical roles of neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes, Salmonella typhimurium, and Yersinia enterocolitica. Infect. Immun. 65:630-635[Abstract]. |
| 16. |
Cornelis, G. R.
1998.
The Yersinia deadly kiss.
J. Bacteriol.
180:5495-5504 |
| 17. |
Cornelis, G. R.,
A. Boland,
A. P. Boyd,
C. Geuijen,
M. Iriarte,
C. Neyt,
M. P. Sory, and I. Stainier.
1998.
The virulence plasmid of Yersinia, an antihost genome.
Microbiol. Mol. Biol. Rev.
62:1315-1352 |
| 18. | Cornelis, G. R., and H. Wolf-Watz. 1997. The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Mol. Microbiol. 23:861-867[CrossRef][Medline]. |
| 19. |
Driggers, P. H.,
D. L. Ennist,
S. L. Gleason,
W. H. Mak,
M. S. Marks,
B. Z. Levi,
J. R. Flanagan,
E. Appella, and K. Ozato.
1990.
An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes.
Proc. Natl. Acad. Sci. USA
87:3743-3747 |
| 20. |
Eisenbeis, C. F.,
H. Singh, and U. Storb.
1995.
Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator.
Genes Dev.
9:1377-1387 |
| 21. |
Eklund, E. A.,
A. Jalava, and R. Kakar.
1998.
PU.1, interferon regulatory factor 1, and interferon consensus sequence-binding protein cooperate to increase gp91(phox) expression.
J. Biol. Chem.
273:13957-13965 |
| 22. |
Fehr, T.,
G. Schoedon,
B. Odermatt,
T. Holtschke,
M. Schneemann,
M. F. Bachmann,
T. W. Mak,
I. Horak, and R. M. Zinkernagel.
1997.
Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis.
J. Exp. Med.
185:921-931 |
| 23. |
Fields, K. A.,
M. L. Nilles,
C. Cowan, and S. C. Straley.
1999.
Virulence role of V antigen of Yersinia pestis at the bacterial surface.
Infect. Immun.
67:5395-5408 |
| 24. |
Fujioka, N.,
R. Akazawa,
K. Ohashi,
M. Fujii,
M. Ikeda, and M. Kurimoto.
1999.
Interleukin-18 protects mice against acute herpes simplex virus type 1 infection.
J. Virol.
73:2401-2409 |
| 25. | Fultz, M. J., and S. N. Vogel. 1998. Analysis of the antagonist effect of IFN-alpha on IFN-gamma-induced interferon consensus sequence binding protein messenger RNA in murine macrophages. J. Inflamm. 48:28-39[Medline]. |
| 26. |
Gabriele, L.,
J. Phung,
J. Fukumoto,
D. Segal,
I. M. Wang,
P. Giannakakou,
N. A. Giese,
K. Ozato, and H. C. Morse.
1999.
Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein.
J. Exp. Med.
190:411-422 |
| 27. | Gallant, T., M. H. Freedman, H. Vellend, and W. H. Francombe. 1986. Yersinia sepsis in patients with iron overload treated with deferoxamine. N. Engl. J. Med. 314:1643[Medline]. |
| 28. |
Giese, N. A.,
L. Gabriele,
T. M. Doherty,
D. M. Klinman,
L. Tadesse-Heath,
C. Contursi,
S. L. Epstein, and H. C. Morse.
1997.
Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression.
J. Exp. Med.
186:1535-1546 |
| 29. |
Grützkau, A.,
C. Hanski,
H. Hahn, and E. O. Riecken.
1990.
Involvement of M cells in the bacterial invasion of Peyer's patches: a common mechanism shared by Yersinia enterocolitica and other enteroinvasive bacteria.
Gut
31:1011-1015 |
| 30. |
Hanski, C.,
U. Kutschka,
H. P. Schmoranzer,
M. Naumann,
A. Stallmach,
H. Hahn,
H. Menge, and E. O. Riecken.
1989.
Immunohistochemical and electron microscopic study of interaction of Yersinia enterocolitica serotype O8 with intestinal mucosa during experimental enteritis.
Infect. Immun.
57:673-678 |
| 31. |
Hanski, C.,
M. Naumann,
A. Grützkau,
G. Pluschke,
B. Friedrich,
H. Hahn, and E. O. Riecken.
1991.
Humoral and cellular defense against intestinal murine infection with Yersinia enterocolitica.
Infect. Immun.
59:1106-1111 |
| 32. | Heesemann, J., K. Hantke, T. Vocke, E. Saken, A. Rakin, I. Stojiljkovic, and R. Berner. 1993. Virulence of Yersinia enterocolitica is closely associated with siderophore production, expression of an iron-repressible outer membrane polypeptide of 65,000 Da and pesticin sensitivity. Mol. Microbiol. 8:397-408[CrossRef][Medline]. |
| 33. |
Heesemann, J., and R. Laufs.
1983.
Construction of a mobilizable Yersinia enterocolitica virulence plasmid.
J. Bacteriol.
155:761-767 |
| 34. | Holtschke, T., J. Lohler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K. P. Knobeloch, L. Gabriele, J. F. Waring, M. F. Bachmann, R. M. Zinkernagel, H. C. Morse, K. Ozato, and I. Horak. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307-317[CrossRef][Medline]. |
| 35. |
Hueck, C. J.
1998.
Type III protein secretion systems in bacterial pathogens of animals and plants.
Microbiol. Mol. Biol. Rev.
62:379-433 |
| 36. | Jurado, R. L. 1997. Iron, infections, and anemia of inflammation. Clin. Infect. Dis. 25:888-895[Medline]. |
| 37. |
Kantakamalakul, W.,
A. D. Politis,
S. Marecki,
T. Sullivan,
K. Ozato,
M. J. Fenton, and S. N. Vogel.
1999.
Regulation of IFN consensus sequence binding protein expression in murine macrophages.
J. Immunol.
162:7417-7425 |
| 38. | Kawakami, K., |